- Smilow Cancer Hospital Phase I Unit55 Park StreetSte First FloorNew Haven, CT 06511
Joseph Paul Eder, MD
Biography
Joseph Paul Eder, MD still remembers the night his brother was rushed to the hospital after a very serious car accident. After seeing how the trauma surgeon saved his brother’s life, he thought, “I want to be able to make an actual difference like this in peoples’ lives every day.”
Now a medical oncologist at Yale Medicine, Dr. Eder treats cancer patients and explores new treatment options for the disease. As clinical director of the Early Drug Development program, he conducts clinical trials for targeted immunotherapies and targeted molecular therapies, treatments that are personalized to each individual’s immune system, rather than to their type of cancer. The goal is to trigger a patient’s own immune system to fight off the disease, often with fewer and less severe side effects that traditional chemotherapy treatments often bring.
As a clinician, Dr. Eder hopes to provide comfort and guidance to his patients during an extremely stressful and uncertain time in their lives. “Some of my patients will ask me questions like, ‘How do I go about living with this?’ It’s an incredible honor to be trusted with such an important and personal question,” he says. “I try to understand them well enough to provide some kind of guidance.” But, he says, caring about these patients comes naturally. “Cancer patients are the kindest people,” he says. “They’re grateful for the smallest things. It’s easy to be kind to kind people.”
Dr. Eder also teaches medical oncology at the Yale School of Medicine.
Titles
- Professor of Medicine (Medical Oncology)
Education & Training
- FellowDana-Farber Cancer Institute (1985)
- FellowshipBeth Israel Hospital (1985)
- FellowshipGeorgetown University Hospital (1982)
- ResidencyGeorgetown University Hospital (1981)
- MDGeorgetown University School of Medicine (1978)
Languages Spoken
- English
- Deutsch (German)
Additional Information
- Who’s Who Madison:
- AB of Internal Medicine, Hematology (Internal Medicine) (1984)
- AB of Internal Medicine, Medical Oncology (1983)
- AB of Internal Medicine, Internal Medicine (1981)
- Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2022, 28: 2969. PMID: 35775194, DOI: 10.1158/1078-0432.CCR-22-1792.
- Eder JP. Reply to E. Rosenbaum et al. JCO Precision Oncology 2022, 6: e2200136. PMID: 35675573, PMCID: PMC9200392, DOI: 10.1200/PO.22.00136.
- Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Luis Perez Gracia J, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 35577503, PMCID: PMC9114963, DOI: 10.1136/jitc-2021-004076.
- Grant MJ, Finberg KE, Walther Z, Stein SM, Lacy J, Eder JP, Goldberg SB. Yale Precision Medicine Tumor Board: reawakening the guardian of the genome. The Lancet. Oncology 2022, 23: 337-338. PMID: 35240081, DOI: 10.1016/S1470-2045(22)00037-7.
- Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 35217573, PMCID: PMC8883256, DOI: 10.1136/jitc-2021-003026.
- Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 6366-6375. PMID: 34518310, DOI: 10.1158/1078-0432.CCR-20-4185.
- Roussos Torres ET, Rafie C, Wang C, Lim D, Brufsky A, LoRusso PM, Eder JP, Chung V, Downs M, Geare M, Piekarz R, Streicher H, Anforth L, Rudek MA, Zhu Q, Besharati S, Cimino-Mathews A, Anders RA, Stearns V, Jaffee EM, Connolly RM. Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 5828-5837. PMID: 34135021, PMCID: PMC8563383, DOI: 10.1158/1078-0432.CCR-20-5017.
- Eder JP, Doroshow DB, Do KT, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precision Oncology 2021, 5: 466-472. PMID: 34994649, DOI: 10.1200/PO.20.00247.
- Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet. Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/S1470-2045(20)30683-5.
- Shapiro GI, LoRusso P, Dowlati A, T Do K, Jacobson CA, Vaishampayan U, Weise A, Caimi PF, Eder JP, French CA, Labriola-Tompkins E, Boisserie F, Pierceall WE, Zhi J, Passe S, DeMario M, Kornacker M, Armand P. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. British Journal Of Cancer 2021, 124: 744-753. PMID: 33311588, PMCID: PMC7884382, DOI: 10.1038/s41416-020-01180-1.
- Olamiju B, Odell I, Panse G, Eder JP, Leventhal JS. Skin puckering and edema during durvalumab therapy. JAAD Case Reports 2021, 7: 110-112. PMID: 33364282, PMCID: PMC7750709, DOI: 10.1016/j.jdcr.2020.11.019.
- LoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM. Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PloS One 2021, 16: e0248097. PMID: 33826614, PMCID: PMC8026051, DOI: 10.1371/journal.pone.0248097.
- Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology 2021, 5 PMID: 34527850, PMCID: PMC8437220, DOI: 10.1200/PO.20.00439.
- Peguero J, Sohal DPS, O'Neil BH, Safran H, Kelly K, Grilley-Olson JE, Subbiah V, Nadauld L, Purkayastha D, Stealey E, Ricart AD, Kang BP, Eder JP. Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study. JCO Precision Oncology 2019, 3: 1-10. PMID: 35100715, DOI: 10.1200/PO.18.00383.
- Jürgensmeier JM, Eder JP, Herbst RS. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 4425-35. PMID: 25183480, PMCID: PMC5369358, DOI: 10.1158/1078-0432.CCR-13-0753.
- Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 6107-16. PMID: 16135477, DOI: 10.1200/JCO.2005.01.136.
- Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. British Journal Of Cancer 2005, 93: 54-9. PMID: 15986034, PMCID: PMC2361482, DOI: 10.1038/sj.bjc.6602671.
- Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemotherapy And Pharmacology 2001, 48: 347-55. PMID: 11761451, DOI: 10.1007/s002800100319.
- Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2001, 7: 231-42. PMID: 11234874.
- Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, Kufe DW, Von Hoff DD, Rowinsky EK. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2001, 19: 857-69. PMID: 11157040, DOI: 10.1200/JCO.2001.19.3.857.
- Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2000, 6: 1632-8. PMID: 10815880.
- Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemotherapy And Pharmacology 2000, 46: 319-28. PMID: 11052630, DOI: 10.1007/s002800000152.
- Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 1998, 4: 317-24. PMID: 9516917.
- Eder JP, Chan V, Wong J, Wong YW, Ara G, Northey D, Rizvi N, Teicher BA. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemotherapy And Pharmacology 1998, 42: 327-35. PMID: 9744779, DOI: 10.1007/s002800050825.
- Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 1997, 3: 98-106. PMID: 9267670.
- Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW. Trials of 9-amino-20(S)-camptothecin in Boston. Annals Of The New York Academy Of Sciences 1996, 803: 247-55. PMID: 8993518, DOI: 10.1111/j.1749-6632.1996.tb26394.x.
- Eder JP, Chan VT, Ng SW, Rizvi NA, Zacharoulis S, Teicher BA, Schnipper LE. DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Research 1995, 55: 6109-16. PMID: 8521401.
- Ng SW, Eder JP, Schnipper LE, Chan VT. Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene. The Journal Of Biological Chemistry 1995, 270: 25850-8. PMID: 7592770, DOI: 10.1074/jbc.270.43.25850.
- Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells.Eder JP, Chan VT, Niemierko E, Teicher BA, Schnipper LE. Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. The Journal Of Biological Chemistry 1993, 268: 13844-9. PMID: 8390979.
- Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1993, 11: 1085-91. PMID: 8099120, DOI: 10.1200/JCO.1993.11.6.1085.
- Elias AD, Ayash L, Frei E, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP. Intensive combined modality therapy for limited-stage small-cell lung cancer. Journal Of The National Cancer Institute 1993, 85: 559-66. PMID: 8384264, DOI: 10.1093/jnci/85.7.559.
- Chan VT, Ng SW, Eder JP, Schnipper LE. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. The Journal Of Biological Chemistry 1993, 268: 2160-5. PMID: 8380592.
- Schwartz GN, Teicher BA, Eder JP, Korbut T, Holden SA, Ara G, Herman TS. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine. Cancer Chemotherapy And Pharmacology 1993, 32: 455-62. PMID: 8258194, DOI: 10.1007/BF00685890.
- Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, Frei E, Antman KH. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplantation 1992, 10: 57-63. PMID: 1515880.
- Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1992, 10: 995-1000. PMID: 1588381, DOI: 10.1200/JCO.1992.10.6.995.
- Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1992, 10: 102-10. PMID: 1727912, DOI: 10.1200/JCO.1992.10.1.102.
- Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Cancer Research 1991, 51: 1086-91. PMID: 1825474.
- Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1991, 9: 320-7. PMID: 1846407, DOI: 10.1200/JCO.1991.9.2.320.
- Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Research 1991, 51: 510-3. PMID: 1985770.
- Goldberg MA, Gaut CC, Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Bunn HF. Erythropoietin gene regulation: from the laboratory to the bedside. Contributions To Nephrology 1991, 88: 35-45; discussion 46-7. PMID: 2040197, DOI: 10.1159/000419514.
- Eder JP, Elias AD, Ayash L, Wheeler CA, Shea TC, Schnipper LE, Frei E, Antman KH. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients. Cancer Chemotherapy And Pharmacology 1991, 29: 61-5. PMID: 1742850, DOI: 10.1007/BF00686337.
- Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Hunt M, Critchlow J, Schnipper L, Frei E. Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. Journal Of Cancer Research And Clinical Oncology 1991, 117 Suppl 4: S208-13. PMID: 1795009, DOI: 10.1007/BF01613229.
- Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990, 76: 2354-9. PMID: 2257306.
- Dezube BJ, Eder JP, Pardee AB. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Cancer Research 1990, 50: 6806-10. PMID: 2119882.
- Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1990, 8: 1699-706. PMID: 2213105, DOI: 10.1200/JCO.1990.8.10.1699.
- Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1990, 8: 1239-45. PMID: 2162912, DOI: 10.1200/JCO.1990.8.7.1239.
- Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Seminars In Oncology 1990, 17: 18-32. PMID: 2106164.
- Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schryber SM, Begg C, Teicher BA. High-dose thiotepa alone and in combination regimens with bone marrow support. Seminars In Oncology 1990, 17: 33-8. PMID: 2106166.
- Eder JP, Teicher BA, Holden SA, Senator L, Cathcart KN, Schnipper LE. Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline. Cancer Chemotherapy And Pharmacology 1990, 26: 423-8. PMID: 2171796, DOI: 10.1007/BF02994093.
- Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1990, 8: 170-8. PMID: 2104923, DOI: 10.1200/JCO.1990.8.1.170.
- Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Research 1989, 49: 5994-8. PMID: 2790813.
- Graves SW, Eder JP, Schryber SM, Sharma K, Brena A, Antman KH, Peters WP. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clinical Science (London, England : 1979) 1989, 77: 501-7. PMID: 2555106, DOI: 10.1042/cs0770501.
- Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1989, 7: 651-61. PMID: 2651580, DOI: 10.1200/JCO.1989.7.5.651.
- Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE, Frei E. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents. Cancer Research 1989, 49: 595-8. PMID: 2910481.
- Teicher BA, Holden SA, Jones SM, Eder JP, Herman TS. Influence of scheduling on two-drug combinations of alkylating agents in vivo. Cancer Chemotherapy And Pharmacology 1989, 25: 161-6. PMID: 2513139, DOI: 10.1007/BF00689576.
- Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. Journal Of The National Cancer Institute 1988, 80: 1221-6. PMID: 3138431, DOI: 10.1093/jnci/80.15.1221.
- Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Archives Of Dermatology 1988, 124: 878-84. PMID: 3288124, DOI: 10.1001/archderm.124.6.878.
- Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K. Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treatment Reports 1987, 71: 1043-7. PMID: 3119200.
- Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. The Journal Of Clinical Investigation 1987, 79: 1524-8. PMID: 3033027, PMCID: PMC424429, DOI: 10.1172/JCI112983.
- Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treatment Reports 1987, 71: 119-25. PMID: 3542208.
- Antman K, Eder JP, Frei E. High-dose chemotherapy with bone marrow support for solid tumors. Important Advances In Oncology 1987, 221-35. PMID: 2841230.
- Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1986, 4: 1592-7. PMID: 3534155, DOI: 10.1200/JCO.1986.4.11.1592.
- Eder JP, Bast RC, Peters WP, Henner D, Sanchez E, Schryber S, Frei E, Schnipper LE. Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Research 1986, 46: 4496-9. PMID: 3524814.
- Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, Frei E. Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treatment Reports 1986, 70: 877-80. PMID: 3719578.
- Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1986, 4: 646-54. PMID: 3517240, DOI: 10.1200/JCO.1986.4.5.646.
Biography
Joseph Paul Eder, MD still remembers the night his brother was rushed to the hospital after a very serious car accident. After seeing how the trauma surgeon saved his brother’s life, he thought, “I want to be able to make an actual difference like this in peoples’ lives every day.”
Now a medical oncologist at Yale Medicine, Dr. Eder treats cancer patients and explores new treatment options for the disease. As clinical director of the Early Drug Development program, he conducts clinical trials for targeted immunotherapies and targeted molecular therapies, treatments that are personalized to each individual’s immune system, rather than to their type of cancer. The goal is to trigger a patient’s own immune system to fight off the disease, often with fewer and less severe side effects that traditional chemotherapy treatments often bring.
As a clinician, Dr. Eder hopes to provide comfort and guidance to his patients during an extremely stressful and uncertain time in their lives. “Some of my patients will ask me questions like, ‘How do I go about living with this?’ It’s an incredible honor to be trusted with such an important and personal question,” he says. “I try to understand them well enough to provide some kind of guidance.” But, he says, caring about these patients comes naturally. “Cancer patients are the kindest people,” he says. “They’re grateful for the smallest things. It’s easy to be kind to kind people.”
Dr. Eder also teaches medical oncology at the Yale School of Medicine.
Titles
- Professor of Medicine (Medical Oncology)
Education & Training
- FellowDana-Farber Cancer Institute (1985)
- FellowshipBeth Israel Hospital (1985)
- FellowshipGeorgetown University Hospital (1982)
- ResidencyGeorgetown University Hospital (1981)
- MDGeorgetown University School of Medicine (1978)
Languages Spoken
- English
- Deutsch (German)
Additional Information
- Who’s Who Madison:
- AB of Internal Medicine, Hematology (Internal Medicine) (1984)
- AB of Internal Medicine, Medical Oncology (1983)
- AB of Internal Medicine, Internal Medicine (1981)
- Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2022, 28: 2969. PMID: 35775194, DOI: 10.1158/1078-0432.CCR-22-1792.
- Eder JP. Reply to E. Rosenbaum et al. JCO Precision Oncology 2022, 6: e2200136. PMID: 35675573, PMCID: PMC9200392, DOI: 10.1200/PO.22.00136.
- Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Luis Perez Gracia J, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 35577503, PMCID: PMC9114963, DOI: 10.1136/jitc-2021-004076.
- Grant MJ, Finberg KE, Walther Z, Stein SM, Lacy J, Eder JP, Goldberg SB. Yale Precision Medicine Tumor Board: reawakening the guardian of the genome. The Lancet. Oncology 2022, 23: 337-338. PMID: 35240081, DOI: 10.1016/S1470-2045(22)00037-7.
- Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 35217573, PMCID: PMC8883256, DOI: 10.1136/jitc-2021-003026.
- Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 6366-6375. PMID: 34518310, DOI: 10.1158/1078-0432.CCR-20-4185.
- Roussos Torres ET, Rafie C, Wang C, Lim D, Brufsky A, LoRusso PM, Eder JP, Chung V, Downs M, Geare M, Piekarz R, Streicher H, Anforth L, Rudek MA, Zhu Q, Besharati S, Cimino-Mathews A, Anders RA, Stearns V, Jaffee EM, Connolly RM. Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 5828-5837. PMID: 34135021, PMCID: PMC8563383, DOI: 10.1158/1078-0432.CCR-20-5017.
- Eder JP, Doroshow DB, Do KT, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precision Oncology 2021, 5: 466-472. PMID: 34994649, DOI: 10.1200/PO.20.00247.
- Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet. Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/S1470-2045(20)30683-5.
- Shapiro GI, LoRusso P, Dowlati A, T Do K, Jacobson CA, Vaishampayan U, Weise A, Caimi PF, Eder JP, French CA, Labriola-Tompkins E, Boisserie F, Pierceall WE, Zhi J, Passe S, DeMario M, Kornacker M, Armand P. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. British Journal Of Cancer 2021, 124: 744-753. PMID: 33311588, PMCID: PMC7884382, DOI: 10.1038/s41416-020-01180-1.
- Olamiju B, Odell I, Panse G, Eder JP, Leventhal JS. Skin puckering and edema during durvalumab therapy. JAAD Case Reports 2021, 7: 110-112. PMID: 33364282, PMCID: PMC7750709, DOI: 10.1016/j.jdcr.2020.11.019.
- LoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM. Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PloS One 2021, 16: e0248097. PMID: 33826614, PMCID: PMC8026051, DOI: 10.1371/journal.pone.0248097.
- Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology 2021, 5 PMID: 34527850, PMCID: PMC8437220, DOI: 10.1200/PO.20.00439.
- Peguero J, Sohal DPS, O'Neil BH, Safran H, Kelly K, Grilley-Olson JE, Subbiah V, Nadauld L, Purkayastha D, Stealey E, Ricart AD, Kang BP, Eder JP. Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study. JCO Precision Oncology 2019, 3: 1-10. PMID: 35100715, DOI: 10.1200/PO.18.00383.
- Jürgensmeier JM, Eder JP, Herbst RS. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 4425-35. PMID: 25183480, PMCID: PMC5369358, DOI: 10.1158/1078-0432.CCR-13-0753.
- Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2005, 23: 6107-16. PMID: 16135477, DOI: 10.1200/JCO.2005.01.136.
- Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. British Journal Of Cancer 2005, 93: 54-9. PMID: 15986034, PMCID: PMC2361482, DOI: 10.1038/sj.bjc.6602671.
- Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemotherapy And Pharmacology 2001, 48: 347-55. PMID: 11761451, DOI: 10.1007/s002800100319.
- Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2001, 7: 231-42. PMID: 11234874.
- Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, Kufe DW, Von Hoff DD, Rowinsky EK. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2001, 19: 857-69. PMID: 11157040, DOI: 10.1200/JCO.2001.19.3.857.
- Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2000, 6: 1632-8. PMID: 10815880.
- Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemotherapy And Pharmacology 2000, 46: 319-28. PMID: 11052630, DOI: 10.1007/s002800000152.
- Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 1998, 4: 317-24. PMID: 9516917.
- Eder JP, Chan V, Wong J, Wong YW, Ara G, Northey D, Rizvi N, Teicher BA. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemotherapy And Pharmacology 1998, 42: 327-35. PMID: 9744779, DOI: 10.1007/s002800050825.
- Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 1997, 3: 98-106. PMID: 9267670.
- Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW. Trials of 9-amino-20(S)-camptothecin in Boston. Annals Of The New York Academy Of Sciences 1996, 803: 247-55. PMID: 8993518, DOI: 10.1111/j.1749-6632.1996.tb26394.x.
- Eder JP, Chan VT, Ng SW, Rizvi NA, Zacharoulis S, Teicher BA, Schnipper LE. DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Research 1995, 55: 6109-16. PMID: 8521401.
- Ng SW, Eder JP, Schnipper LE, Chan VT. Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene. The Journal Of Biological Chemistry 1995, 270: 25850-8. PMID: 7592770, DOI: 10.1074/jbc.270.43.25850.
- Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells.Eder JP, Chan VT, Niemierko E, Teicher BA, Schnipper LE. Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. The Journal Of Biological Chemistry 1993, 268: 13844-9. PMID: 8390979.
- Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1993, 11: 1085-91. PMID: 8099120, DOI: 10.1200/JCO.1993.11.6.1085.
- Elias AD, Ayash L, Frei E, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP. Intensive combined modality therapy for limited-stage small-cell lung cancer. Journal Of The National Cancer Institute 1993, 85: 559-66. PMID: 8384264, DOI: 10.1093/jnci/85.7.559.
- Chan VT, Ng SW, Eder JP, Schnipper LE. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. The Journal Of Biological Chemistry 1993, 268: 2160-5. PMID: 8380592.
- Schwartz GN, Teicher BA, Eder JP, Korbut T, Holden SA, Ara G, Herman TS. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine. Cancer Chemotherapy And Pharmacology 1993, 32: 455-62. PMID: 8258194, DOI: 10.1007/BF00685890.
- Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, Frei E, Antman KH. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplantation 1992, 10: 57-63. PMID: 1515880.
- Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1992, 10: 995-1000. PMID: 1588381, DOI: 10.1200/JCO.1992.10.6.995.
- Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1992, 10: 102-10. PMID: 1727912, DOI: 10.1200/JCO.1992.10.1.102.
- Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Cancer Research 1991, 51: 1086-91. PMID: 1825474.
- Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1991, 9: 320-7. PMID: 1846407, DOI: 10.1200/JCO.1991.9.2.320.
- Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Research 1991, 51: 510-3. PMID: 1985770.
- Goldberg MA, Gaut CC, Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Bunn HF. Erythropoietin gene regulation: from the laboratory to the bedside. Contributions To Nephrology 1991, 88: 35-45; discussion 46-7. PMID: 2040197, DOI: 10.1159/000419514.
- Eder JP, Elias AD, Ayash L, Wheeler CA, Shea TC, Schnipper LE, Frei E, Antman KH. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients. Cancer Chemotherapy And Pharmacology 1991, 29: 61-5. PMID: 1742850, DOI: 10.1007/BF00686337.
- Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Hunt M, Critchlow J, Schnipper L, Frei E. Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. Journal Of Cancer Research And Clinical Oncology 1991, 117 Suppl 4: S208-13. PMID: 1795009, DOI: 10.1007/BF01613229.
- Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990, 76: 2354-9. PMID: 2257306.
- Dezube BJ, Eder JP, Pardee AB. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Cancer Research 1990, 50: 6806-10. PMID: 2119882.
- Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1990, 8: 1699-706. PMID: 2213105, DOI: 10.1200/JCO.1990.8.10.1699.
- Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1990, 8: 1239-45. PMID: 2162912, DOI: 10.1200/JCO.1990.8.7.1239.
- Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Seminars In Oncology 1990, 17: 18-32. PMID: 2106164.
- Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schryber SM, Begg C, Teicher BA. High-dose thiotepa alone and in combination regimens with bone marrow support. Seminars In Oncology 1990, 17: 33-8. PMID: 2106166.
- Eder JP, Teicher BA, Holden SA, Senator L, Cathcart KN, Schnipper LE. Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline. Cancer Chemotherapy And Pharmacology 1990, 26: 423-8. PMID: 2171796, DOI: 10.1007/BF02994093.
- Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1990, 8: 170-8. PMID: 2104923, DOI: 10.1200/JCO.1990.8.1.170.
- Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Research 1989, 49: 5994-8. PMID: 2790813.
- Graves SW, Eder JP, Schryber SM, Sharma K, Brena A, Antman KH, Peters WP. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clinical Science (London, England : 1979) 1989, 77: 501-7. PMID: 2555106, DOI: 10.1042/cs0770501.
- Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1989, 7: 651-61. PMID: 2651580, DOI: 10.1200/JCO.1989.7.5.651.
- Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE, Frei E. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents. Cancer Research 1989, 49: 595-8. PMID: 2910481.
- Teicher BA, Holden SA, Jones SM, Eder JP, Herman TS. Influence of scheduling on two-drug combinations of alkylating agents in vivo. Cancer Chemotherapy And Pharmacology 1989, 25: 161-6. PMID: 2513139, DOI: 10.1007/BF00689576.
- Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. Journal Of The National Cancer Institute 1988, 80: 1221-6. PMID: 3138431, DOI: 10.1093/jnci/80.15.1221.
- Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Archives Of Dermatology 1988, 124: 878-84. PMID: 3288124, DOI: 10.1001/archderm.124.6.878.
- Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K. Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treatment Reports 1987, 71: 1043-7. PMID: 3119200.
- Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. The Journal Of Clinical Investigation 1987, 79: 1524-8. PMID: 3033027, PMCID: PMC424429, DOI: 10.1172/JCI112983.
- Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treatment Reports 1987, 71: 119-25. PMID: 3542208.
- Antman K, Eder JP, Frei E. High-dose chemotherapy with bone marrow support for solid tumors. Important Advances In Oncology 1987, 221-35. PMID: 2841230.
- Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1986, 4: 1592-7. PMID: 3534155, DOI: 10.1200/JCO.1986.4.11.1592.
- Eder JP, Bast RC, Peters WP, Henner D, Sanchez E, Schryber S, Frei E, Schnipper LE. Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Research 1986, 46: 4496-9. PMID: 3524814.
- Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, Frei E. Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treatment Reports 1986, 70: 877-80. PMID: 3719578.
- Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1986, 4: 646-54. PMID: 3517240, DOI: 10.1200/JCO.1986.4.5.646.
- Smilow Cancer Hospital Phase I Unit55 Park StreetSte First FloorNew Haven, CT 06511